CD47 and neoplasm: Anti-CD47 antibody can block the interaction between CD47 and SIRPα, allowing phagocytes to selectively engulf tumor cells without damaging the surrounding healthy cells in melanoma and pediatric cancer (Uluçkan et al., 2009; Ridler, 2017; Hayat et al., 2020).